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Alemtuzumab is approved for highly active MS and, in Europe, can
be employed after other disease-modifying treatments (DMTs) as
an escalation approach or first therapeutic option. The occurrence
of secondary autoimmune adverse events and infections differs
depending on the employed approach.
In the manuscript entitled “Alemtuzumab treatment of multiple
sclerosis in real-world clinical practice: report from a single Italian
center” by di Ioia M. and collaborators, efficacy and safety data of
alemtuzumab were evaluated in a real-world MS population. The
aim of the article is to describe in detail the unexpected serious
adverse events which occurred in this cohort during and after the
administration of the alemtuzumab treatment.
Adverse events were observed in 45,7% of the patients. These
events were ranked as severe in 23% of the patients. We reported,
in particular, cases of autoimmune hemolytic anemia (AIHA),
pancytopenia, viral hepatitis E and noninfectious meningo-
encephalomyelitis.
Published by Elsevier Inc. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).j.msard.2019.101504.
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Specifications Table
Subject Neurology
Specific subject area Adverse events of alemtuzumab in MS treatment
Type of data Description of clinical cases
How data were acquired Observational study. Data were acquired using The iMed software and patients records.
Data Format Analysed
Parameters for data collection Collected data derived from real-world clinical practice
Description of data collection Data were collected through the i-Med electronic database and patients records
Data source location Chieti/Abruzzo
Italy
Data accessibility Data is with this article
Related research article di Ioia M., Di Stefano V., Farina D., Di Tommaso V., Travaglini D., Pietrolongo E., Sensi
S.L., Onofrj M., De Luca G.
Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: a report
from a single Italian center.
Multiple Sclerosis and Related Disorders
https://doi.org/10.1016/j.msard.2019.101504
Value of the Data
 Safety profile of alemtuzumab may differ in real-world MS population when compared to clinical trials because of
different comorbidities and previous drug history of the patients
 Clinicians expert in treatment of MS before switching to alemtuzumab must take into account previous therapies and
patients comorbidities
 Real-world studies like this may clarify safety profile of alemtuzumab in different MS patients and help to understand the
better sequencing of MS drugs
 This data lead to reflect on the better-in-place of alemtuzumab in MS therapy
M. di Ioia et al. / Data in brief 29 (2020) 10534121. Data descriptionThirty-five patients treated with alemtuzumab in a single MS Center were followed for at least
thirty-six months. Adverse events were observed in 45,7% of the patients and ranked as severe in 23%
of them [1]. In addition to the expected adverse events such as thyroid dysfunctions, immune
thrombocytopenia (ITP) and infections, rare and unexpected adverse events, described below, were
also observed.
A 34-year-old man developed, eleven months after the first alemtuzumab course, albuminuria and
AIHA (May 2017) [2]. ITP occurred three months later (August 2017). The patient was treated for ITP
with Rituximab; ten months later (June 2018), he was also diagnosed with glomerulonephritis and
treated with cyclophosphamide until September 2018. One year after cessation of cyclophosphamide
(October 2019), laboratory tests were stable with persistent albuminuria, brain and spinal cord MRI
was stable but he had worsening ataxia, so he was scheduled to start ocrelizumab. A case of AIHA,
associated with warm reactive autoantibodies (IgG), was observed in a female 36-year-old patient, four
months after the second alemtuzumab course. She was treated with erythrocytes transfusion, steroids,
and intravenous immunoglobulins, a regimen that produced remission. The patient, six months later,
relapsed with AIHA and was then treated with mycophenolate. We also observed a case of pancyto-
penia that occurred in a 45-year-old male patient eighteen months after the second alemtuzumab
course. The patient was treated with prednisone. All the patients had a history of previous treatments
with three to six other DMTs before alemtuzumab.
A female 36-year-old patient developed, after the second alemtuzumab course, viral hepatitis E
(Hev). She exhibited high levels (1600 U/L) of alanine aminotransferase (ALT). Besides this case and
another patient who developed recurrent cystitis, no other infections were observed.
Finally, a 45-year-oldmale patient was diagnosedwithmeningo-encephalomyelitis. He developed a
spinal cord syndrome with a T10 sensitive level associated with tinnitus; he showed multiple
Gdþ lesions in the brain and spinal cord as well as signs of diffuse of leptomeningeal enhancing signals
that occurred five months after the first alemtuzumab course (August 2018). Infectious and neoplastic
M. di Ioia et al. / Data in brief 29 (2020) 105341 3causes were excluded by laboratory tests and targeted instrumental exams. The patient was treated
with methylprednisolone (5000 mg), acyclovir (750 mg; three times a day), and ampicillin. Treatment
resulted in partial clinical and radiological improvements. In November 2018, the patient was admitted
to our inpatient clinic and exhibited ataxia and signs of worsening of the gait (EDSS 6.5). An MRI scan
revealed two new Gd þ lesions in the cerebral white matter. He was treated with methylprednisolone
(6000 mg iv) followed by oral steroid tapering that produced no recovery. The patient underwent
plasmapheresis (five cycles; from November 23rd to December 5th, 2018), a regimen that produced a
mild clinical improvement. A second MRI scan showed a new lesion in the medulla oblongata, the CSF
was normal, viral and bacterial infections were excluded, and the patient was scheduled to start
ocrelizumab. Detection of anti-myelin oligodendrocyte glycoprotein (MOG) antibody was positive
(1:80), while detection of anti-aquaporin-4 (AQP-4) antibody was negative. Six months after the first
ocrelizumab infusion (June 2019) brainMRI showed new enhancing and non enhancing lesions and the
patient was clinically stable whereas follow-up MRI six months later was stable.
2. Experimental design, materials, and methods
We described unexpected serious adverse events observed in 16 of 35 patients treated with
alemtuzumab from October 2014 to January 2019 at the MS Center in Chieti. All the adverse events
(expected and unexpected) and their percentages were reported in Supplementary data. All the data
were collected through the i-Med electronic database and patients records and then analysed by a
clinician specialist in MS. i-Med database is the Italian Multiple Sclerosis Registry containing both
personal data and disease related data (onset, diagnosis, relapses, disease modyfing drugs, etc.). All
patients gave their consent to data entry and use of their data for research purposes. More details about
study design can be found in the related article [1]. For the unexpected events we provided a detailed
description in this article and a final interpretation and discussion in the related article published in
Multiple Sclerosis and Related Disorders [1].
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Supplementary data to this article can be found online at https://doi.org/10.1016/j.dib.2020.105341.
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